Professor Finlay works at the frontier of medical technology. In the interests of full transparency, his companies, roles and financial disclosures are listed here.
FOUNDED 2018 · UCL SPIN-OUT
Founder · Director & Chief Medical Officer
UCL spin-out developing transformative interventional tools for coronary intervention — the iKOr system and flow-sensing microcatheter. £2.8M+ raised.
FOUNDED 2018 · BARTS HEALTH SPIN-OUT
Founder · Non-Executive Director
Barts Health spin-out developing new methods to target areas for more efficient, effective AF ablation — the STAR Mapping™ approach, with licensed patents.
CO-FOUNDED · EDUCATION TECHNOLOGY
Co-founder
The world’s first web-delivered whole-heart electrical simulation for teaching and training — used in medical schools worldwide and licensed by Boston Scientific.
FOUNDED 2026 · DIGITAL HEALTH
Founder · Sole Owner
Professor Finlay’s new venture in cardiac digital health — a patient app and clinic platform now in development, with the website launching soon.
In line with regulatory requirements, Dr Finlay is required to inform you of any financial interests they hold in the facilities or equipment used in your care. Dr Finlay holds financial interests in Welbeck London Heart Health (3.36% ownership) & Welbeck London Imaging and Diagnostics (0.13% ownership). Dr Finlay's investment in Welbeck London Heart Health includes a group shareholding of 5% in Welbeck London Pharmacy for that relevant Speciality Group. This information is provided in the interest of transparency and to support informed patient choice.
Professor Finlay has received research funding, grants, travel support, educational support, lecture and consultancy fees from Biosense Webster (J&J) Ltd, Abbott Ltd, Medtronic Ltd and Biotronik GmbH, amongst others. These relationships never influence individual treatment decisions, which are always made in your best interests and agreed with you.
£5M+
raised across ventures
3
medtech companies founded
2
licensed patent families
Global
simulation used worldwide
Treatments like pulsed field ablation reach Professor Finlay’s patients early.
A clinician who helps build the technology understands exactly how to use it.
Every commercial relationship is declared — decisions are made only in your interest.
